Phase IIIb Study of Ribociclib + ET in Early Breast Cancer

Recruiting now · Phase 3

Conditions studied: Early Breast Cancer

In brief

The purpose of this open-label, multicenter, phase IIIb, single-arm study is to characterize the efficacy and safety of the combination of ribociclib and standard adjuvant endocrine therapy (ET) on invasive breast cancer-free survival (iBCFS), in a close to clinical practice patient population with HR-positive (HR+), HER2-negative (HER2-), Anatomic Stage Group III, IIB, and a subset of Stage IIA Early Breast Cancer (EBC).

Key facts

Study ID
NCT05827081
Run by
Novartis Pharmaceuticals
People needed
1400
Starts
2024-02-28
Expected to finish
2030-09-20
Last updated by the study team
2026-07-17

Who can join

Age: 18 and older, up to 100. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.